DexCom(US:DXCM)2026-02-12 22:20Financial Performance - Fiscal 2025 revenue reached $4.66 billion, a 16% increase from 2024[454] - Gross profit for fiscal 2025 was $2.80 billion, up 15% from the previous year[454] - Operating income increased by 52% to $911.8 million in fiscal 2025[454] - Net income rose to $836.3 million, reflecting a 45% growth compared to 2024[454] - Operating cash flow for fiscal 2025 was $1.44 billion, up 46% from 2024[454] - Revenue from distributor sales in the U.S. was $3.20 billion, while international distributor sales totaled $763.3 million[466] - Revenue increased due to the addition of approximately 600,000 - 700,000 net customers, excluding Stelo customers, in 2025[468] Research and Development - Research and development expenses for fiscal 2025 were $599.1 million, an 8% increase from 2024[456] - Research and development expenses rose by $37.3 million primarily due to higher compensation costs, emphasizing the importance of R&D for future growth[470] Cash and Liquidity - The company ended fiscal 2025 with cash, cash equivalents, and short-term marketable securities totaling $2.00 billion[454] - Cash flows from operating activities were $1.44 billion for the twelve months ended December 31, 2025, an increase of $451.2 million compared to 2024[490] - Cash, cash equivalents, and short-term marketable securities totaled $2.00 billion as of December 31, 2025, a decrease of $580.7 million from the previous year[489] - The company expects to continue generating positive cash flows from operations for the foreseeable future[476] - As of December 31, 2025, the company had a working capital ratio of 1.88 and a quick ratio of 1.50, indicating sufficient current assets to cover short-term liabilities[480] - The company received net proceeds of $1.23 billion from the 2028 Notes offering, with plans to use the funds for general corporate purposes and capital expenditures[477] Debt and Financial Ratios - The debt-to-assets ratio was 0.20 as of December 31, 2025, indicating that total assets are sufficient to cover debts[482] Foreign Currency Exposure - A substantial portion of operations is in the U.S., with most sales made in U.S. dollars, leading to significant exposure to foreign currency fluctuations primarily affecting revenue[496] - Expansion of manufacturing sites in Ireland and Malaysia introduces additional foreign exchange currency risk, potentially impacting financial results[497] - Financial statements of international subsidiaries are translated into U.S. dollars using end-of-period exchange rates for assets and liabilities, affecting net income only upon sale or liquidation[498] - The company enters into foreign currency forward contracts to hedge monetary assets and liabilities, with derivative gains and losses included in other income[499] - Notional principal amounts of foreign currency contracts provide a measure of transaction volume but do not represent exposure to market loss[500] - The company actively monitors and manages financial exposures due to exchange rate fluctuations as part of its overall risk management program[500] Product Development - The company launched the G7 continuous glucose monitoring system in 2023 and plans to introduce the G7 15 Day system in late 2025[438] - Dexcom's Stelo biosensor for prediabetes and Type 2 diabetes was launched in August 2024, marking its entry into the over-the-counter market[438] Operating Expenses - Selling, general and administrative expenses increased by $83.7 million, offset by a $87.2 million decrease in legal expenses related to a settled lawsuit[470] - Gross profit margin percentage decreased in 2025 compared to 2024 due to supply availability inefficiencies and lower production yield[468]